| |
Boletim Científico Diário
 |
 Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction
Simone R.B.M. Eussen, Johanna M. Geleijnse, Erik J. Giltay, Cathy J.M. Rompelberg, Olaf H. Klungel and Daan Kromhout
Abstract - clique aqui
|
A Randomized, Double-Blind, Placebo-Controlled Crossover Study of Coenzyme Q10 Therapy in Hypertensive Patients With the Metabolic Syndrome
Joanna M. Young, Christopher M. Florkowski, Sarah L. Molyneux, Roberta G. McEwan, Christopher M. Frampton, M. Gary Nicholls, Russell S. Scott and Peter M. George
Abstract - clique aqui
|
Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan`s National Health Insurance claims database and review of current evidence
Wen-Yi Shau, Hsi-Chieh Chen, Shu-Ting Chen, Hsu-Wen Chou, Chia-Hsuin Chang, Chuei-Wen Kuo and Mei-Shu Lai
Abstract - clique aqui
|
The collective evidence revealed the tendency of increased AMI risk with current use of some NSAIDs. A higher AMI risk associated with use of parenteral NSAIDs was observed in the present study. Ketorolac had the highest associated risk in both oral and parenteral NSAIDs studied. Though further investigation to confirm the association is warranted, prescribing physicians and the general public should be cautious about the potential risk of AMI when using NSAIDs
Ramakrishnan Lakshmy, MSc, PhD, Prashant Mathur, MBBS, PhD, Ruby Gupta, MSc, PhD, Bela Shah, MBBS, MD, Krishnan Anand, MBBS, MD, Viswanathan Mohan, MD, PhD, DSc, Nimesh G. Desai, MBBS, MD, Jagdish Mahanta, MBBS, MD, Prashant Prabhakar Joshi, MBBS, MD, Kavumpurathu Raman Thankappan, MBBS, MD, MPH
Abstract - clique aqui
|
Angiotensin Receptor Blocker to Prevent Microalbuminuria?
Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G, for the ROADMAP Trial Investigators: Olmesartan for delay or prevention of microalbuminuria in type 2 diabetes
Abstract - clique aqui
|
|
 |
|
|
|
Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction
Simone R.B.M. Eussen, Johanna M. Geleijnse, Erik J. Giltay, Cathy J.M. Rompelberg, Olaf H. Klungel and Daan Kromhout
Abstract - clique aqui
|
A Randomized, Double-Blind, Placebo-Controlled Crossover Study of Coenzyme Q10 Therapy in Hypertensive Patients With the Metabolic Syndrome
Joanna M. Young, Christopher M. Florkowski, Sarah L. Molyneux, Roberta G. McEwan, Christopher M. Frampton, M. Gary Nicholls, Russell S. Scott and Peter M. George
Abstract - clique aqui
|
Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan`s National Health Insurance claims database and review of current evidence
Wen-Yi Shau, Hsi-Chieh Chen, Shu-Ting Chen, Hsu-Wen Chou, Chia-Hsuin Chang, Chuei-Wen Kuo and Mei-Shu Lai
Abstract - clique aqui
|
The collective evidence revealed the tendency of increased AMI risk with current use of some NSAIDs. A higher AMI risk associated with use of parenteral NSAIDs was observed in the present study. Ketorolac had the highest associated risk in both oral and parenteral NSAIDs studied. Though further investigation to confirm the association is warranted, prescribing physicians and the general public should be cautious about the potential risk of AMI when using NSAIDs
Ramakrishnan Lakshmy, MSc, PhD, Prashant Mathur, MBBS, PhD, Ruby Gupta, MSc, PhD, Bela Shah, MBBS, MD, Krishnan Anand, MBBS, MD, Viswanathan Mohan, MD, PhD, DSc, Nimesh G. Desai, MBBS, MD, Jagdish Mahanta, MBBS, MD, Prashant Prabhakar Joshi, MBBS, MD, Kavumpurathu Raman Thankappan, MBBS, MD, MPH
Abstract - clique aqui
|
Angiotensin Receptor Blocker to Prevent Microalbuminuria?
Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G, for the ROADMAP Trial Investigators: Olmesartan for delay or prevention of microalbuminuria in type 2 diabetes
Abstract - clique aqui
|
|
|
|
|
|
|
| |
|
